International Clinical Trial: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2051250117) titled 'A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer' on Sept. 25.

Study Type: Interventional

Study Design: randomized controlled trial, double blind, active control, parallel assignment, treatment purpose

Primary Sponsor: Hibi Kazushige

Condition: Squamous and non-squamous, Non-Small Cell Lung

Intervention: Participants will be randomized in a 1:1 ratio to either rilvegostomig or pembrolizumab arm.

Recruitment Status: Recruiting

Phase: 3

Date of F...